{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:54:58Z","timestamp":1780462498105,"version":"3.54.1"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) is a haematological cancer associated with organ damage, essentially bone damage. <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> continues to be considered an incurable disease and requires significant therapeutic resources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This manuscript presents a literature review of the utility of zoledronic acid (zoledronate) in the management of bone disease in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The clinical benefit of bisphosphonates in the prevention and treatment of bone disease in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> has been demonstrated in the last 10\u00a0years. A recent network meta\u2010analysis has evaluated 20 randomised clinical trials with nearly 7000 patients with myeloma enrolled and confirms the role of these agents in the prevention of pain, bone fractures and other skeletal\u2010related events (<jats:styled-content style=\"fixed-case\">SRE<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>. However, their role on survival remains unclear. Zoledronate has shown significant reductions in <jats:styled-content style=\"fixed-case\">SRE<\/jats:styled-content> compared with placebo or other agents with acceptable tolerability, and recent studies have shown antitumoural effects for this agent, with a marginal survival benefit demonstrated in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Zoledronate prevents <jats:styled-content style=\"fixed-case\">SRE<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> and presents a marginal survival benefit that deserves further investigation in controlled studies. Current clinical guidelines should be followed regarding the appropriate use of zoledronate in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>, to enhance its effects and to minimise its potential toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12239","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T15:17:55Z","timestamp":1387034275000},"page":"181-188","source":"Crossref","is-referenced-by-count":15,"title":["Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review"],"prefix":"10.1111","volume":"92","author":[{"given":"Adri\u00e1n","family":"Alegre","sequence":"first","affiliation":[{"name":"Hospital Universitario de la Princesa Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gironella","sequence":"additional","affiliation":[{"name":"Hospital Vall D\u2032Hebron Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bail\u00e9n","sequence":"additional","affiliation":[{"name":"Hospital Carlos Haya M\u00e1laga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Hospital Miguel Servet Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_2_9_5_1","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic B","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2009.07.040"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"e_1_2_9_8_1","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta\u2010analysis","volume":"5","author":"Mhaskar R","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma version 2.2013.2013. Available from:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22718"},{"key":"e_1_2_9_12_1","unstructured":"American Cancer Society.Cancer Facts & Figures.2010. Available from:http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-026238.pdf."},{"key":"e_1_2_9_13_1","unstructured":"GLOBOCAN.Country Fast Stats.2008. Available from:http:\/\/globocan.iarc.fr\/factsheets\/populations\/factsheet.asp?uno=968."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2004.01.001"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"e_1_2_9_19_1","first-page":"1501","volume-title":"Hematology, Basic Principle and Practice","author":"Tricot G","year":"2005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-X"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.032"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood.V116.21.3028.3028","article-title":"Comparative effectiveness of bisphoshonates in multiple myeloma [abstract]","volume":"116","author":"Mhaskar R","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392522"},{"key":"e_1_2_9_26_1","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double\u2010blind, comparative trial","volume":"7","author":"Rosen LS","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.02823.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0209"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"e_1_2_9_31_1","first-page":"30","article-title":"A retrospective study of skeletal and disease\u2010free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"6","author":"Ria R","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.025"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(11)70004-X"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08574.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.011"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033571"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12239","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:28:53Z","timestamp":1695540533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/ejh.12239"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12239","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}